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Bilharzial ova are the main pathogenic agent leading to fibrosis and are the primary elements in provoking overt disease.
2 Enlargement of the liver and spleen is related to the intensity of infection with schistosoma mansonj.
1 , • The spleen enlarges progressively. Splenic size bears little relationship to the portal pressure. It is larger in young people and in macronodular cirrhosis. An enlarged spleen is the single most important diagnostic sign of portal hypertension. ' Hepatosplenic schistosomiasis caused by S. mansoni is more difficult to treat and is associated with greater morbidity and mortality than urinary schistosomiasis caused by S. hematobium. 6 In the last few years, the treatment of schistosomiasis has been simplified by using newer schistosomicidal drugs (i.e. prariquantel) in a single dose.' In Egypt, the total dose is higher than that found effective elsewhere, which may be due to differences in the worm strain.
• The serum concentration of the drug in hepatosplenic patients may be three times higher than that in the intestinal group.' A continuously changing drug concentration can give rise to a varying response. If a prolonged response is required, it is preferable to wait until the effect of the first dose begins to diminish and then to repeat the dose.~
The aim of this study was to measure the effectiveness of praziquantel in the elimination of S. mansoni in human patients. A reduction in the size of the spleen was used as a parameter of the therapeutic effect.
Materials and methods
Subjects for this study were recrwted from a pool of patients attending the tropical clinic at ElManzalah District Hospital in the period between August 1988 and July 1989. They were investigated for bilharzia! infestation by urine and stool examination. Of those who were positive, 30 patients who were found to have splenomegaly during clinical examination agreed to participate in this study.
All patients were given a thorough clinical examination. The following laboratory investigations were performed: liver function tests; glutamic ox- Number of doses to achieve a reponse 1.9 ± 0.9 3.6 ± 1.6 12.5 ± 2.0
Number of doses to achieve improvement 8.9 ± 4.8
12.7 ± 2.4t 15 ± l.Ot (4-18) {8-17) (14) (15) (16) • Mean ± standard deviation and range.
t There were three patients in group 2, and 6 patients in group 3 who did not achieve improvement. The number of doses administered to these patients is not included in these numbers. Table 2 . Results in relation to sex of the patient.
Age (years)
Size of spleen (cm/MCL)
Number of doses at which a response was achieved
Number of patients improved
Number of doses at which improvement was achieved •statistically nonsignificant difference. alacetic transaminase (GOT}, glutamic pyruvic transaminase (GPT), albumin and bilirubin, hemoglobin and creatinine measurements. Electrocardiography (ECG) and abdominal ultrasonography were also performed. The patients were divided into three groups according to the size of the spleen. The spleen size was measured in the supine position and was recorded in centimeters below the left costal margin at mid-clavicular line (MCL). The size of the spleen was confirmed by percussion. The first group (01) was those having a spleen enlarged to 5 crn/MCL. The second group (G2) was those having a spleen size of 6-10 cm/MCL. The third group (03) was those with splenomegaly greater than 10 cm/MCL.
All patients were given praziquantel 40 mg/kg weekly. The doses were given on a full stomach. Each dose was divided in two equal parts given four hours apart. The patients were followed weekly for response, improvement, and for any adverse reactions.
Response was defined as: a) Reduction in the size of the spleen as measured in the MCL, i.e., shortening of the distance between the tip of the spleen and the lower border of the costal margin, b) Change in the consistency of the spleen from firm to soft, c) Flattening: the reduction of the bulging of the spleen into the abdomen in the antero-posterior diameter, with or without reduction in size, d) Mobility: an adherent spleen became mobile after treatment, and e) Tenderness in the left hypochondrium.
Improvement was considered to have occurred if the spleen completely regressed behind the costal margin.
Patients who did not improve (non-responders) were later followed by sigmoidoscopy to exclude the presence of active bilharziasis.
ResuJts
Our sample included 30 patients; 22 males and 8 females. There were 10 Gl, 12 G2 and 8 G3 patients.
The results are considered in regards to both response and improvement.
Response was achieved in all patients. The number of doses required to achieve a response differed among the groups ( Table 1) . The difference between the first and second groups was highly significant (P ~ 0.001) and was also significant between the first and third groups (P < 0.05), but was insignificant between the second and third groups.
All GI patients (100%) achieved improvement. The improvement rate in G2 was 75% (9 out of 12). Only two out of eight (25·0Jo) patients in the third group improved. The difference in the improvement rate among the three groups was statistically significant, x 2 = 12.13, (P~ 0.005).
The number of doses required to achieve improvement varied among the different groups (Table 1 ). There were three G2 patients who did not show imPage 64 -JIMA: Volume 23, 1991 provement after receiving 12, 14, and 19 doses each. There were six G3 patients who did not show improvement after receiving 11, 15, 18, 20, 
There was a positive correlation between the pretreatment size of the spleen and the number of doses at which a reponse was achieved (r = 0.49, P < O.Ol) (Figure 1 ). There was also a positive correlation between the pretreatment size of the spleen and the number of doses at which improvement was achieved; (r = 0.59, PL.. O.Ol) (Figure 2 ).
There were no statisticaJ differences between males and females in regard to age, size of the spleen, number of doses at which a response occurred, or number of doses at which improvement was achieved ( Table 2) .
During the course of the study, no abnormalities in laboratory investigations were detected. There was improvement in the hemoglobin concentration after treatment. The difference between hemoglobin concentration before (8.5 ± 2.3 g/dl) and after treatment (11.0 ± 0.8 g/dl) was statistically significant (t = 4.33, p .0005).
For those nine patients who did not improve, sigmoidoscopy was offered. Two of the nine refused sigmoidoscopy. In two, there was no evidence of scbistosoma ova. One patient bad only dead ova, but four out of the seven patients still had living ova.
Ultrasound pictures of the spleen before and after treatment are presented in Figures 3 and 4 respectively, showing a typical treatment response.
Discussion
The liver pathology in schistosomiasis is attributable to lodgement of the schistosoma mansoni ova in the small intrahepatic portal radicals. 10 The eggs impact in the presinusoidal branches of the portal vein and granulomas form there obstructing portal blood flow and causing portal hypertension with varices and congestive splenomegaly.
11 Hypertrophy of the hepatic artery and a relative increase in blood flow, help to maintain sinusoidal perfusion. In the early stages of active hepatic schistosomiasis, the progressive enlargement of the spleen is due to congestion. Ova or worms are rarely found in Lhe splenic pulp. The role of increased splenic blood flow in the genesis of portal hypertension is controversial. 5 ln the later stages, there is diffuse fibrosis associated with marked destruction of musculoelastic tissue of the trabeculae and capsule.
11 The capacity of the liver sinusoids as a main drainage route of blood from the spleen is reduced as a result of this fibrosis. It is assumed that when fibrosis is halted under the effect of treatment by praziquantel, some capacity of the sinusoids and drainage of blood from the spleen is restored. This is why the size of the spleen was reduced.
Praziquantel has a serum half life of about 0.8-1.5 hours in adults with normal renal and hapatic functions; however, the serum half life of the drug metabolites is 4-5 hours. 12 The therapeutic threshold of a particular drug is the amount of that drug necessary to produce a desired response. 13 In some cases, it may be necessary to use the maximum tolerated dose to achleve a therapeutic effect." The absence of a therapeutic effect was seen in four out of seven patients who were found by sigmoidoscopy to still have active bilharziasis even after multiple repeated doses (21 ± 3). This reveals that the treatment of schlstosoma mansoni can be very ilifficult, but that repetition of treatment is essential to minimize the burden of infestation and prevent complications. Previously only two doses were recommended in heavy infestation. "
The safety of praziquantel was proved in regard to the effect on renal function, liver function, and ECG . 16 Monitoring of our patients by weekly clinical examination and laboratory investigation revealed no toxicity or side effects of praziquantel therapy.
In conclusion, thls study shows that a single dose of praziquantel is insufficient to achieve an acceptable cure rate of schistosoma mansoni and that multiple doses are mandatory. This finding needs further confirmation on larger samples of cases of schistosoma mansoni infestation to help to redesign the best therapeutic strategy.
